|
8-4-2026 16:37 EDT
| Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff |
|
1-4-2026 4:05 EDT
| Grant of share-based long-term incentive instruments to members of the Board of Management and key employees |
|
31-3-2026 3:01 EDT
| EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis |
|
16-3-2026 13:37 EDT
| Annual General Meeting in ALK-Abelló A/S held on 16 March 2026 |
|
4-3-2026 5:20 EST
| New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors |
|
20-2-2026 8:55 EST
| Annual General Meeting in ALK-Abelló A/S on 16 March 2026 |
|
20-2-2026 1:32 EST
| Henriette Mersebach to step down as ALK’s head of R&D |
|
20-2-2026 1:18 EST
| Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin |
|
13-2-2026 6:16 EST
| Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026 |
|
29-1-2026 10:16 EST
| ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children |
|
8-1-2026 11:18 EST
| ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco |
